PMID: 16510051Mar 3, 2006Paper

Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases

Current Atherosclerosis Reports
Laura CalabresiGuido Franceschini

Abstract

Apolipoprotein A-I(Milano) (apoA-I(M)) is a natural variant of apoA-I characterized by a cysteine for arginine substitution at position 173 of the primary sequence. ApoA-I(M) carriers have much less atherosclerosis than expected from their very low plasma high-density lipoprotein (HDL) cholesterol levels, suggesting that the variant might be protective. Synthetic HDL (sHDL) made with a recombinant form of the dimeric A-I(M) (A-I(M)/A-I(M)) and phospholipids given in single or multiple injections is effective in inducing the regression of atherosclerotic plaques, preventing arterial restenosis, and limiting cardiac dysfunction after ischemia/reperfusion injury. In a phase II trial in patients with acute coronary syndromes, a short-term treatment with A-I(M)/A-I(M) sHDL caused a remarkable reduction of atheroma burden. Although at early stages of drug development, A-I(M)/A-I(M) sHDL holds vast promise for the treatment of a variety of cardiovascular diseases in humans.

References

Jun 1, 1991·Atherosclerosis·G FranceschiniC R Sirtori
Jan 1, 1986·Methods in Enzymology·A Jonas
Aug 1, 1994·The Journal of Clinical Investigation·C PásztyE M Rubin
Sep 23, 1997·Biochemical and Biophysical Research Communications·L CalabresiD Taramelli
Feb 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·D LiJ L Mehta
May 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·G FranceschiniF Bernini
Apr 13, 2001·JAMA : the Journal of the American Medical Association·S J RobinsUNKNOWN VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Aug 19, 2003·Trends in Cardiovascular Medicine·Chieko Mineo, Philip W Shaul
Sep 13, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Laura CalabresiGuido Franceschini
Oct 21, 2003·The Journal of Pharmacology and Experimental Therapeutics·Giuseppe RossoniLaura Calabresi
Nov 1, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Kerry-Anne Rye, Philip J Barter
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Oct 16, 2004·Circulation Research·Philip J BarterAlan M Fogelman
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Apr 16, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Mohamad NavabAlan M Fogelman
Sep 9, 2006·Pharmacology & Therapeutics·Laura CalabresiGuido Franceschini

❮ Previous
Next ❯

Citations

Aug 12, 2006·Current Atherosclerosis Reports·Natalie Khuseyinova, Wolfgang Koenig
Nov 20, 2009·BMC Clinical Pharmacology·Leonid GaidukovEtgar Levy-Nissenbaum
Feb 28, 2013·International Urology and Nephrology·Georges KhoueiryJames Lafferty
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Antonio J Vallejo-Vaz, Kausik K Ray
Oct 23, 2008·Expert Review of Cardiovascular Therapy·Alan T RemaleyDmitri Sviridov
Mar 6, 2008·Expert Opinion on Drug Delivery·Robert O Ryan
Jan 29, 2011·Expert Opinion on Biological Therapy·Stephen J NichollsSteven E Nissen
Dec 3, 2010·Journal of Clinical Lipidology·Ahmad Al-SarrafJiri Frohlich
Apr 2, 2008·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Paola Conca, Guido Franceschini
Jul 1, 2008·Expert Opinion on Medical Diagnostics·Alan T Remaley, G Russell Warnick
Jul 16, 2008·Orvosi hetilap·György ParaghMárk László
May 23, 2012·Progress in Lipid Research·Aneta Otocka-KmiecikMaciej Banach
Jun 30, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Laura Z VanagsChristina A Bursill
Jun 9, 2007·Current Opinion in Cardiology·Göran Walldius, Ingmar Jungner
Jul 11, 2007·Current Opinion in Lipidology·Stephen J Nicholls, Steven E Nissen
Mar 24, 2010·Nature Reviews. Nephrology·Nosratola D VaziriAlan M Fogelman
Apr 2, 2009·Nature Reviews. Drug Discovery·John D Baxter, Paul Webb
Sep 13, 2012·American Journal of Therapeutics·Nitin Verma, Vincent M Figueredo
Nov 5, 2013·Current Opinion in Lipidology·Brian R Krause, Alan T Remaley
Jan 17, 2020·The Journal of Pharmacology and Experimental Therapeutics·Sangram RautAndras Lacko
May 15, 2020·Stroke; a Journal of Cerebral Circulation·Célina DucrouxPierre Amarenco
Feb 5, 2019·Current Medicinal Chemistry·Eleni PappaVasilis K Tsimihodimos
May 27, 2016·Angewandte Chemie·Santanu MondalGovindasamy Mugesh
Sep 19, 2015·Current Opinion in Lipidology·MyNgan DuongStephen J Nicholls
Sep 12, 2006·Free Radical Biology & Medicine·Anne Negre-SalvayreRobert Salvayre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.